Schonfeld Strategic Advisors LLC acquired a new position in shares of Global Cord Blood Co. (NYSE:CO) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 39,900 shares of the medical research company’s stock, valued at approximately $142,000.
Separately, Marshall Wace LLP lifted its position in Global Cord Blood by 8.0% in the 2nd quarter. Marshall Wace LLP now owns 36,012 shares of the medical research company’s stock worth $112,000 after buying an additional 2,661 shares during the last quarter.
Separately, BidaskClub downgraded Global Cord Blood from a “hold” rating to a “sell” rating in a research report on Friday, December 18th.
Global Cord Blood (NYSE:CO) last released its quarterly earnings data on Tuesday, November 24th. The medical research company reported $0.16 earnings per share for the quarter. The firm had revenue of $42.07 million during the quarter. Global Cord Blood had a return on equity of 12.77% and a net margin of 42.17%.
Global Cord Blood Company Profile
Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services.
See Also: What is a Candlestick Chart?
Receive News & Ratings for Global Cord Blood Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Cord Blood and related companies with MarketBeat.com's FREE daily email newsletter.